vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Innovex International, Inc. (INVX). Click either name above to swap in a different company.
Innovex International, Inc. is the larger business by last-quarter revenue ($273.6M vs $196.0M, roughly 1.4× Axsome Therapeutics, Inc.). Innovex International, Inc. runs the higher net margin — 5.1% vs -14.6%, a 19.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 9.1%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 46.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
AXSM vs INVX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $273.6M |
| Net Profit | $-28.6M | $14.0M |
| Gross Margin | — | 28.9% |
| Operating Margin | -13.8% | 9.4% |
| Net Margin | -14.6% | 5.1% |
| Revenue YoY | 65.0% | 9.1% |
| Net Profit YoY | 61.9% | -56.1% |
| EPS (diluted) | $-0.55 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $273.6M | ||
| Q3 25 | $171.0M | $240.0M | ||
| Q2 25 | $150.0M | $224.2M | ||
| Q1 25 | $121.5M | $240.4M | ||
| Q4 24 | $118.8M | $250.7M | ||
| Q3 24 | $104.8M | $151.8M | ||
| Q2 24 | $87.2M | $130.3M | ||
| Q1 24 | $75.0M | $128.0M |
| Q4 25 | $-28.6M | $14.0M | ||
| Q3 25 | $-47.2M | $39.2M | ||
| Q2 25 | $-48.0M | $15.3M | ||
| Q1 25 | $-59.4M | $14.8M | ||
| Q4 24 | $-74.9M | $31.8M | ||
| Q3 24 | $-64.6M | $82.6M | ||
| Q2 24 | $-79.3M | $9.5M | ||
| Q1 24 | $-68.4M | $16.4M |
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 31.6% | ||
| Q2 25 | — | 32.0% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 34.7% | ||
| Q2 24 | — | 35.3% | ||
| Q1 24 | — | 38.4% |
| Q4 25 | -13.8% | 9.4% | ||
| Q3 25 | -27.0% | 26.0% | ||
| Q2 25 | -24.5% | 10.1% | ||
| Q1 25 | -46.9% | 9.1% | ||
| Q4 24 | -61.1% | 10.7% | ||
| Q3 24 | -59.8% | -8.7% | ||
| Q2 24 | -89.5% | 10.0% | ||
| Q1 24 | -89.7% | 17.4% |
| Q4 25 | -14.6% | 5.1% | ||
| Q3 25 | -27.6% | 16.3% | ||
| Q2 25 | -32.0% | 6.8% | ||
| Q1 25 | -48.9% | 6.1% | ||
| Q4 24 | -63.1% | 12.7% | ||
| Q3 24 | -61.7% | 54.4% | ||
| Q2 24 | -91.0% | 7.3% | ||
| Q1 24 | -91.1% | 12.8% |
| Q4 25 | $-0.55 | $0.20 | ||
| Q3 25 | $-0.94 | $0.57 | ||
| Q2 25 | $-0.97 | $0.22 | ||
| Q1 25 | $-1.22 | $0.21 | ||
| Q4 24 | $-1.54 | $-0.03 | ||
| Q3 24 | $-1.34 | $1.99 | ||
| Q2 24 | $-1.67 | $0.30 | ||
| Q1 24 | $-1.44 | $0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | — |
| Total DebtLower is stronger | — | $18.9M |
| Stockholders' EquityBook value | $88.3M | $1.1B |
| Total Assets | $689.8M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | $185.6M | ||
| Q1 24 | $331.4M | $202.2M |
| Q4 25 | — | $18.9M | ||
| Q3 25 | — | $20.1M | ||
| Q2 25 | — | $34.8M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $88.3M | $1.1B | ||
| Q3 25 | $73.7M | $1.0B | ||
| Q2 25 | $73.1M | $995.6M | ||
| Q1 25 | $53.2M | $978.4M | ||
| Q4 24 | $57.0M | $958.2M | ||
| Q3 24 | $92.9M | $904.4M | ||
| Q2 24 | $102.9M | $352.5M | ||
| Q1 24 | $144.0M | $344.3M |
| Q4 25 | $689.8M | $1.3B | ||
| Q3 25 | $669.3M | $1.3B | ||
| Q2 25 | $639.8M | $1.2B | ||
| Q1 25 | $596.7M | $1.2B | ||
| Q4 24 | $568.5M | $1.2B | ||
| Q3 24 | $561.5M | $1.1B | ||
| Q2 24 | $548.2M | $1.0B | ||
| Q1 24 | $545.7M | $1.0B |
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $52.2M |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 3.74× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $52.2M | ||
| Q3 25 | $1.0M | $48.4M | ||
| Q2 25 | $-32.4M | $59.2M | ||
| Q1 25 | $-43.4M | $31.1M | ||
| Q4 24 | $-26.2M | $36.3M | ||
| Q3 24 | $-18.6M | $21.7M | ||
| Q2 24 | $-30.1M | $22.8M | ||
| Q1 24 | $-53.5M | $12.6M |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | $16.6M | ||
| Q1 24 | $-53.6M | $7.8M |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | 12.7% | ||
| Q1 24 | -71.4% | 6.1% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | 4.7% | ||
| Q1 24 | 0.1% | 3.7% |
| Q4 25 | — | 3.74× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 3.86× | ||
| Q1 25 | — | 2.11× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 2.39× | ||
| Q1 24 | — | 0.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
INVX
| Products | $202.7M | 74% |
| Leasing | $42.3M | 15% |
| Services | $28.6M | 10% |
